Positive Spondylitis Phase III Brings Lilly's Taltz Closer To Cosentyx's Label

First of three Phase III studies of Taltz in ankylosing spondylitis is positive, using a high bar for primary endpoint efficacy. But Novartis' Cosentyx, already approved in this indication, is expected to dominate the market.